VISP, APRIL 22, 2021: Swissfillon are carving a great niche for fill&finish of advanced therapeutics and we have been creating awareness in key journals such as OnDrugDelivery.www.swissfillon.com .
LUND, APRIL 21, 2021:Mount Sinai has joined RhoVac’s multicenter trial of RV1001 in post-surgical and -radiotherapy patients with prostate cancer. RV1001 blocks the RhoC protein which appears to be involved in metastasis. www.rhovac.com .
ZURICH, APRIL 20th 2021: We worked with the Swiss Biotech Association to produce this year’s Swiss Biotech Report with the them leadership, agility and innovation in the time of COVID-19. Copies can be downloaded at www.swissbiotech.org
OSLO/LONDON, APRIL 7th 2021: EXACT THERAPEUTICS AS, a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced the appointment of Dominic Moreland as Chief Financial Officer who will be based at the London office of EXACT-Tx in White City. www.exact-tx.com
SEOUL, MARCH 29: GemVax & KAEL Co., Ltd. has announced that a paper on GV1001, a novel Alzheimer’s treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal ‘Alzheimer’s Research & Therapy’. www.gemvax.com